![Steven Godin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Steven Godin
Corporate Officer/Principal chez Bridge Pharmaceuticals, Inc.
Profil
Steven Godin currently works as a Senior Director-Toxicology at Bridge Pharmaceuticals, Inc.
Postes actifs de Steven Godin
Sociétés | Poste | Début |
---|---|---|
Bridge Pharmaceuticals, Inc.
![]() Bridge Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge Laboratories gives drug development clients-biotech/pharmaceutical firms, government agencies and virtual companies with strong outsourcing needs-a CRO choice that can dramatically improve the speed and cost-effectiveness of their drug development research programs. | Corporate Officer/Principal | 20/01/2010 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Bridge Pharmaceuticals, Inc.
![]() Bridge Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge Laboratories gives drug development clients-biotech/pharmaceutical firms, government agencies and virtual companies with strong outsourcing needs-a CRO choice that can dramatically improve the speed and cost-effectiveness of their drug development research programs. | Commercial Services |